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Summary. The active 5'-triphosphate of arabinosyl-2- 
fluoroadenine (F-ara-ATP) increases the anabolism of ara- 
binosylcytosine (ara-C), whereas ara-C 5'-triphosphate in- 
hibits the phosphorylation of arabinosyl-2-fluoroadenine 
(F-ara-A) in human leukemia cells in vitro. These interac- 
tions have a potential impact on drug scheduling. Clinical 
trials of relapsed leukemia in which fludarabine (F-ara-A 
5'-monophosphate) and ara-C were given in sequence pro- 
vided the opportunity to evaluate the effects of ara-C infu- 
sion on two sequelae: the pharmacokinetics of F-ara-A in 
plasma and that of F-ara-ATP in leukemia cells. First, 
F-ara-A pharmacokinetics were altered by ara-C infusion. 
This was visualized as a transient increase in F-ara-A 
plasma levels during the ara-C infusion that was given 4 h 
after fludarabine. The perturbation in F-ara-A plasma 
levels was dependent on the dose of ara-C. Second, peak 
F-ara-ATP concentrations were lower in leukemia cells of 
patients who received ara-C in addition to fludarabine as 
compared with those who received fludarabine alone. The 
terminal half-life of F-ara-A in plasma and the half-life of 
intracellular F-ara-ATP were reduced after the ara-C infu- 
sion in a concentration-dependent manner. Studies using 
purified deoxycytidine kinase support the conclusion that 
the increase in plasma levels of F-ara-A is in part the result 
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of an effective competition by ara-C for phosphorylation 
by this enzyme, leading to a perturbation of the pharma- 
cokinetics of intracellular F-ara-ATP. 
Introduction 
Arabinosylcytosine (ara-C) is the main component in treat- 
ment protocols for acute myelogenous leukemia [19], 
whereas fludarabine is the most active single agent against 
low-grade lymphocytic malignancies, especially chronic 
lymphocytic leukemia (CLL) [20, 21]. The metabolism 
and mechanisms of action of both compounds are closely 
related, The first step, which is rate-limiting in their 
phosphorylation to the respective active triphosphates, is 
mediated by deoxycytidine kinase (dCyd kinase) [2, 10, 
24, 26]. The acfvity of this enzyme is regulated by the 
cellular nucleotide pools [9, 11, 25]. In addition, ara-C 
5'-triphosphate (ara-CTP) may exert feedback inhibition 
on dCyd kinase [7, 14, 28]. In contrast, the 5'-triphosphate 
of fludarabine (F-ara-ATP) stimulates dCyd kinase activity 
both indirectly by lowering the deoxynucleotide pool 
through the inhibition of ribonucleotide reductase [2, 14, 
32] and by an apparent direct action on the enzyme [14]. A 
positive correlation between the cellular pharmacokinetics 
of ara-CTP in circulating leukemia blasts and the clinical 
response to treatment has been established [12, 13, 18, 30]. 
Strategies were therefore sought to increase the accumula- 
tion of ara-CTP through metabolic modulation by fludara- 
bine. 
When incubated in vitro with arabinosyl-2- 
fluoroadenine (F-ara-A), K562 ceils or freshly isotated 
leukemic lymphocytes accumulated ara-CTP at a higher 
rate to greater concentrations than did cells exposed to 
ara-C alone [14, 15]. On the basis of these studies, we 
designed three different treatment protocols for patients 
with CLL or acute leukemias, in which fhidarabine was 
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Fig. 1 A - D .  Plasma concentrations of 
F-ara-A in four patients diagnosed with A, 
B CLL or C, D acute leukemia were moni- 
tored over 24 h starting at the end of a 
30-min i. v. infusion of 30 mg/m 2 fludara- 
bine (F-ara-AMP). Patients received flud- 
arabine either A alone or in combination 
with two infusions of ara-C given (at 20 h 
before and 4 h after fludarabine) at doses of 
B 0.5, C 1, and D 3 g/rn 2. Each data point 
represents the result obtained in one plasma 
sample 
ated in circulating leukemia cells from patients who re- 
ceived the combination therapy [16, 17]. 
Studying the modulation of ara-C metabolism by flud- 
arabine in clinical trials provided the opportunity to inves- 
tigate two pharmacokinetic sequelae that have a potential 
impact on drag scheduling. First, on the basis of the kinetic 
characteristics of dCyd kinase, we hypothesized that the 
relatively high plasma concentrations of ara-C (>10 gM) 
would compete effectively for phosphorylation against the 
lower levels of F-ara-A (0.3-0.7 ~M), the nucleoside pro- 
duct of fludarabine dephosphorylation. Second, on the 
basis of studies in K562 cells, we expected that intracellu- 
lar ara-CTP would inhibit F-ara-ATP accumulation, pre- 
sumably through feedback inhibition of dCyd kinase. 
Thus, the pharmacokinetics of plasma F-ara-A and, con- 
sequently, of intracellular F-ara-ATP may be perturbed. 
Patients and methods 
Treatment. After informed consent had been obtained, patients were 
entered in one of the four treatment plans. Patients with refractory CLL 
received 30 mg/m 2 fludarabine (F-ara-AMP, the clinical formulation of 
F-ara-A) in a 30-rain i.v. infusion either as a single agent (n = 6) or in 
combination with ara-C (0.5 g/m 2 given over 2 h) infused at 20 h before 
and 4 h after the administration of fludarabine (n = 7). Adults with acute 
leukemia in relapse were treated with the same drug combination, except 
that the ara-C dose was either 1 g/m 2 infused over 2 h (n = 6) or 3 g/m 2 
infused over 6 h (n = 6). 
Materials. As chromatographic standards F-ara-A was supplied by Ber- 
lex Laboratories, Inc. (Alameda, Calif.) and [8-3H]-F-ara-A was obtained 
from Moravek Biochemicals (Brea, Calif.). F-ara-ATP was synthesized 
by Dr. A. Sen in this laboratory [29]. Ara-CTP and other ribonucleotides 
used as standards were purchased from Sigma (St. Louis, Mo). Erythro- 
9-(2-hydroxy-3-nonyl)adenine was a gift from Dr. T. A. Krenitsky 
(Burroughs Wellcome, Research, Triangle Park, N.C.) and tetrahy- 
drouridine was obtained from Dr. V. Narayanan of the Drug Synthesis 
and Chemistry Branch of the National Cancer Institute (Bethesda, Md.). 
The SEP-PAK ClS cartridges were supplied by Waters Associates (Mil- 
ford, Mass.). All other chemicals used were of the highest purity availa- 
ble. 
Preparation ofplasma andperipheral mononuclear cells. Blood samples 
(5 -10  nil) obtained through a peripheral catheter were immediately 
transferred into a heparinized glass tube containing 1 UM erythro-9-(2- 
hydroxy-3-nonyl)adenine (to inhibit adenosine deaminase) and 500 gM 
tetrahydrouridine (to inhibit cytidine deaminase), which was placed in an 
ice bath. After centrifugation at 500 g for 20 rain at 4 ~ C, the plasma was 
removed and stored at -20 ~ C. The cell pellet was resuspended in 40 ml 
phosphate-buffered saline (NaC1, 8.1 g/l; NazHPO4, 1.14 g/l; KC1, 
0.22 g/l; KH2PO4, 0.27 g/l) and layered over a 10-ml Ficoll-Hypaque 
mixture (sp. gr., 1.077 g/ml). After centrifugation at 400 g for 20 min at 
4 ~ C, the buoyant mononuclear cells were removed and diluted to 10 rnl 
with phosphate-buffered saline. Duplicate analyses of the mean cell 
number and cell volume were done with a model ZM Coulter counter 
equipped with a 100-channel particle-size analyzer (model C1000). 
Cellular nucleotides were extracted with 0.4 M HCIO4, neutralized with 
KOH, and stored a t -20~ [14]. 
Quantitation of nucleosides in plasma and cellular nucleotides. F-ara-A 
plasma levels were determined by high-pressure liquid chromatography 
with fluorescence detection using a method described in detail elsewhere 
[22]. In brief, the nucleoside was isolated from plasma by solid-phase 
extraction (elution from SEP-PAK C18 cartridges with alkaline 
methanol). After derivatization with chloroacetaldehyde to the fluores- 
cent arabinosyl-etheno-isoguanine, the product was separated from other 
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Fig. 2A, B. Influence of the ara-C dose on A the F-ara-A 
AUC and B the terminal half-fife of F-ara-A in plasma. 
Patients received two doses of ara-C, one at 20 h before 
fludarabine treatment and one at 4 h after the start of the 
fludarabine infusion. F-ara-A plasma concentrations were 
quantitated for up to 24 h after fludarabine infusion to 
calculate the AUC and elimination rates of F-ara-A. The 
data point at 0 g/m 2 represents F-ara-A pharmacokinetics 
when fludarabine was given as monotherapy. Each data 
point represents the mean ( + SD) increase in AUC or 
terminal tl/2 observed in 6 (no ara-C, 1 and 3 g/m 2 ara-C) 
or 7 (0.5 g/m 2 ara-C) patients 
tography (gBondapak Cts; Waters Associates, Milford, Mass.). F-ara-A 
concentrations in patient samples were calculated by comparing peak 
areas of the fluorescent derivative to those of standard samples spiked 
with F-ara-A that had been processed simultaneously. Ara-C plasma 
levels were determined by reverse-phase high-pressure liquid chroma- 
tography according to the method described by Breithanpt [1]. The 
steady-state plasma ara-C concentration is expressed as the mean of the 
values obtained in the samples taken at 1 and 2 h (2-h infusion) or, 
generally, as 1- to 6-h (6-h infusion) values found for ara-C in plasma. 
The concentrations of intracellular ara-CTP and F-ara-ATP were deter- 
mined by ion-exchange high-pressure liquid chromatography (Partisil- 10 
SAX column) with UV detection [14]. 
Pharmacokinetic data analysis. Analyses of pharmacokinetic data were 
performed using the computer program ESTRIP [3]. The F-ara-A plasma 
concentration-time data were stripped according to the i. v./postabsorp- 
tion type, except for the samples that showed a transient increase in 
F-ara-A plasma levels. Then, the data sets were divided into two phases 
that were processed separately: the first phase, from the end of the 
infusion to the last time point prior to the increase in F-ara-A concentra- 
tion, was stripped using the i. v./postabsorption type; the second phase, 
starting with the lowest concentration prior to the increase, was 
processed according to the absorption type. Both partial area under the 
curve (AUC) values were added to give the overall AUC. The increases 
in AUC caused by ara-C perturbation of the F-ara-A elimination kinetics 
(AUCp) were determined gravimetrically by overlaying the actual curve 
with a hypothetical, unperturbed elimination curve generated from the 
early data points (before perturbation) and the late data points (>10 h). 
Elimination half-lives of perturbed F-ara-A concentration-time data sets 
were obtained by processing only the data acquired after the occurence of 
the peak or platean concentration according to the i.v./postabsorption 
type. For pharmacokinetic analysis of intracellular F-ara-ATP, the con- 
centration-time data were stripped according to the absorption type. The 
statistical significance of differences between the data sets was assessed 
by Student' s two-tailed t-test. 
Purification of dCyd kinase and determination of its activity, dCyd 
kinase was purified from a routine L-cell expression vector containing 
the cDNA sequence for the enzyme as described in detail elsewhere [6]. 
For determination of the Ki value (inhibition constant) for ara-C on dCyd 
kinase phosphorylation of F-ara-A, 15 gl of the desalted enzyme was 
added to 15 gl ice-cold reaction mix to achieve a final concentration of 
50 mM imidazole/HC1 buffer (pH 7.4), 25 mM dithiothreitol, 2 mM ATP, 
2.5 rnM MgC12, 100-600 gM [3H]-F-ara-A, 0-40 gM ara-C, 1 nag bovine 
serum albumiu/ml and 10% glycerol. After incubation for 20 rain at 
37 ~ C, the reaction was terminated by heating the sample for 1 rain at 
85 ~ C. The radiochemical quantitation of phosphorylated F-ara-A was 
performed as previously described [9]. Lines describing the double recip- 
rocal plots were calculated according to a weighted fit program described 
by Wilkinson [35]. The resulting slope values were plotted against the 
ara-C concentrations, and the apparent Ki va~me was estimated from 
linear regression analysis. 
R e s u l t s  
Influence of ara-C infusion on the plasma 
pharmacokinetics of F-ara-A 
The p la sma  pharmacokine t ics  o f  F - a r a -A  was compared  
be tween  pat ients  rece iv ing  f ludarabine  as monothe rapy  
and those addi t ional ly  treated with an ara-C infusion. 
Figure  1 shows the data o f  four patients,  each repre-  
sentat ive o f  the respect ive  therapy group. The tr iphasic 
p lasma-e l imina t ion  kinet ics  of  F - a r a - A  in pat ients  receiv-  
ing f ludarabine monothe rapy  (Fig. 1 A) was per turbed by  
ara-C infusions in all three combina t ion  therapy protocols  
(Fig. 1 B - D ) .  The F -a ra -A  p la sma  levels either increased 
(Fig. 1 B, C) or p la teaued (Fig. 1 D) during the ara-C infu- 
sions. The  increase  in A U C  caused  by  this t ransient  r ise in 
F - a r a -A  p la sma  concentra t ion seemed to be  dependent  on 
the ara-C dose, with saturat ion occurr ing at 1 g/m2 ara-C 
(Fig. 2A;  P = 0.068 for  the difference between mean 
AUCp values at 0.5 g/m 2 for 2 h vs 1 g/m 2 for 2 h). A t  the 
same time, the terminal  hal f - l ives  of  F - a r a -A  decreased  
with increasing ara-C dose (Fig. 2B;  P = 0.184 at 0.5 g/m2, 
P = 0.006 at 1 g /m 2, and P = 0.001 at 3 g/m 2 as compared  
with that obta ined during f ludarabine  monotherapy) .  Al -  
though the total  A U C s  for F -a ra -A  over  24 h were  in- 
creased after the various ara-C infusions (0.5 g/m2, 
9 . 2 •  h; 1 g /m 2, 1 3 . 1 •  h; 3 g/m2, 
12.4_+ 5.2 gM h) relat ive to that observed  in the absence o f  
ara-C (7.4 • 3.6 gM h), these changes were  not  stat ist ically 
significant.  These  data  suggest  that ara-C caused  a dose-re-  
lated redis t r ibut ion of  F-ara -A.  
Effect of  intracellular ara-CTP on the accumulation of 
F-ara-ATP 
The int racel lular  pharmacokine t ics  of  F - a r a - A T P  was stud- 
ied in pat ients  with C L L  receiving f ludarabine  alone or  in 
combina t ion  with  ara-C to de termine  the inf luence of  
p l a sma  ara-C and cel lular  a ra -CTP on the accumula t ion  of  
F -a ra -ATP.  A compar i son  of  the pharmacokine t ic  data on 
F -a r a -ATP  in c i rculat ing leukemic  lymphocy tes  revea led  
s ignif icant  changes in patients rece iv ing  the combina t ion  
therapy as compared  with those receiv ing f ludarabine  
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Fig. 3 A - D. Concentrations of  F-ara-ATP in circulat- 
ing leukemia cells of four patients diagnosed with A, 
B CLL or C,  D acute leukemia were monitored over 
24 h starting at the end of a 30-rain i. v. infusion of 
30 mg/m 2 fludarabine (F-ara-AMP). Patients 
received fludarabine either A alone o1" in combina- 
tion with two infusions of ara-C given (at 20 h 
before and 4 h after fludarabine) at doses of B 
0.5 g/m 2 over 2 h, C 1 g/m 2 over 2 h, and D 3 g/m 2 
over 6 h 
F-ara-ATP in CLL cells was 43% lower (P = 0.056) fol- 
lowing combination therapy as compared with fludarabine 
monotherapy (Table 1). The time to reach maximal F-ara- 
ATP concentrations was not changed (3 + 1 h after the start 
of the infusion in both groups; data not shown). These data 
agree with previous in vitro studies, which indicate that 
preloading of cells with ara-CTP inhibits the rate of accu- 
mulation of F-ara-ATP [14]. Although the ara-CTP con- 
centrations in CLL lymphocytes ranged between 8 and 
63 gM prior to the fludarabine infusion (Table l), no rela- 
tionship was observed in these seven patients between the 
ara-CTP concentration and the subsequent peak F-ara-ATP 
accumulation as compared in the same individuals. Addi- 
tionally, these studies indicated that F-ara-ATP elimination 
tended to be more rapid in leukemic lymphocytes after 
ara-C infusion (P = 0.109; Table 1). As a consequence of 
lower Cmax values and faster elimination of the F-ara-ATP, 
the mean total AUC for F-ara-ATP over 24 h was 58% 
lower (P = 0.050; Table 1) in CLL cells exposed to both 
ara-C and fludarabine as compared with fludarabine alone. 
The study design for acute leukemias precluded a direct 
comparison of F-ara-ATP pharmacokinetics in blasts fol- 
lowing treatment with fludarabine alone or in combination 
with ara-C. However, considerable changes in the pharma- 
cokinetics of F-ara-ATP were observed with increasing 
ara-C doses (Figs. 3 C, D). At 3 g/m2 ara-C infused over 
6 h, the mean peak level of F-ara-ATP was 44% 
(P = 0.052) of that measured in blasts from patients who 
had received 1 g/m 2 over 2 h (Table 1). The time to reach 
maximal F-ara-ATP levels was similar in both cases (data 
not shown). The mean ara-CTP concentrations remaining 
after the first ara-C infusion of either 1 g/m 2 over 2 h or 
Table 1. Pharmacokinetics of F-ara-ATP in leukemia cells after ara-C infusion 
Disease Ara-C dose a n F-ara-ATP 
(mg/m z) 
Cmax tl/2 AUC 





CLL 0 6 45.4 • 30.3 
CLL 0.5 (2) 7 19.4__+ 10.1 
AL 1.0 (2) 6 31.6___ 18.9 
AL 3.0 (6) 6 14.0--+ 4.4 
36.5-+21.1 
18.5-+ 8.5 
3.8-+ 1.9 d 
3.3-+ 1.0 
880-+435 
372 -+ 272 
401 • 152 
100 • 34 
13_+4 
23 • 8 e 
27 -+ 9 e 
35.7 -+ 20.9 
24.7 -+ 18.3 
31.9 •  
a Numbers in parentheses represent the duration of infusion in hours 
b Median steady-state ara-C concentration in plasma during infusion of  
the second ara-C dose at 4 h after the administration of fludarabine 
c Ara-CTP remaining in leukemia cells from the first ara-C infusion as 
measured at the time of fludarabine infusion 
d tl/2~ = 29.4-+ 16.4 h 
e / ' /=5 
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Fig. 4. Inhibition of dCyd kinase phosphorylation of F-ara-A by ara-C. 
Purified human dCyd kinase was incubated with [3H]F-ara-A alone ( 0 )  
or in the presence of ara-C at 10 ([]), 20 (O), or 40 gM (A). Data points 
represent mean values for duplicate determinations. Inset: Replot of the 
slope of each line against the ara-C concentrations 
3 g/m 2 over 6 h prior to fludarabine administration did not 
significantly differ (P = 0.757; Table 1). F-ara-ATP elimi- 
nation after the lower ara-C dose was biphasic, with a mean 
tl/2o~ value of 3.8+- 1.9 h and a mean tl/2~ value of 
29.4+__ 16.4 h being obtained (Fig. 3C). Treatment with 
3 g/m 2 ara-C resulted in a comparatively short monophasic 
elimination (mean tl/2, 3.3 +- 1.1 h), and F-ara-ATP could 
no longer be detected at about 12 h after the fludarabine 
infusion (Fig. 3 D). These findings indicate that infusion of 
ara-C altered the elimination kinetics of F-ara-ATP in 
circulating blasts. As a consequence, the mean AUC for 
F-ara-ATP in blasts of patients who received 3 g/m2 ara-C 
over 6 h was 25% (P = 0.007) of that determined for 
patients treated with 1 g/m 2 over 2 h. 
Inhibition of F-ara-A phosphorylation by ara-C using 
purified dCyd kinase 
During the ara-C infusions, steady-state plasma concentra- 
tions of ara-C were substantially higher (13+14 gM, 
23+--8 gM, and 27+-9 gM; Table 1) at ara-C doses of 0.5, 
1.0, and 3.0 g/m2, respectively, than those of F-ara-A, 
which were less than 1 gM at each dose. Because ara-C is a 
better substrate for phosphorylation by dCyd kinase, 
phosphorylation of F-ara-A in plasma would be inhibited 
in the presence of ara-C. This may in part explain the 
observed perturbations in plasma F-ara-A and cellular 
F-ara-ATP pharmacokinetics during ara-C infusions. 
For exploration of this hypothesis, dCyd kinase purified 
from a murine L-cell expression system containing the 
cDNA sequence for human T-lymphoblast dCyd kinase 
was used to determine the inhibitory effect of ara-C on 
F-ara-A phosphorylation using ATP as the phosphate 
donor. A Lineweaver-Burk plot of the data revealed an 
apparent Km value (Michaelis constant) of 1600 gM for 
F-ara-A. Ara-C was a competitive inhibitor of F-ara-A 
phosphorylation, with a Ki value of 11.9 gM being obtained 
(Fig. 4). By comparison, the Km of dCyd kinase for ara-C 
in the same system was 14.8 gM. 
Discussion 
The interference of ara-C with F-ara-A metabolism in vivo 
was directly visualized by measuring F-ara-A plasma phar- 
macokinetics during ara-C infusion. A transient increase or 
a plateau of the F-ara-A plasma levels was observed at the 
onset of the ara-C infusion (Fig. 1 B-D),  Fig. 2A). Sub- 
sequently, the terminal half-life of F-ara-A was reduced in 
proportion to the plasma concentration of ara-C (Fig. 2B). 
This disturbance of the usual triphasic elimination kinetics 
of F-ara-A (Fig. 1 A) suggests a redistribution of F-ara-A 
from the tissues into the plasma. 
The terminal half-life of a drug in plasma reflects an 
equilibrium between the retention of the compound in the 
tissue and its excretion. This was previously shown to be 
independent of fludarabine concentration in a dose range of 
between 80 and 260 mg/m 2 [27]. Under the conditions of 
therapy, the elimination kinetics of the drug in tissue, mea- 
sured as the tl/2 of F-ara-ATP in circulating leukemia cells, 
decreased considerably when ara-C was added to the regi- 
men (Fig. 3, Table 1). The faster elimination of F-ara-A 
from plasma after treatment with ara-C (Fig. 2 B) therefore 
reflects a shorter retention of the drug in the tissue. In an 
earlier investigation using higher fludarabine doses 
(50-100 mg/m2), pharmacokinetic studies in circulating 
blasts of eight patients with acute leukemia showed mono- 
phasic elimination of F-ara-ATP, with half-lives ranging 
between 5.2 and over 24 h (mean, 15.1 _+8.0 h; median, 
13.5 h [8]). This suggests that acute leukemia blasts elimi- 
nate F-ara-ATP more rapidly than do CLL lymphocytes 
(Table 1). Additionally, ara-C infusion perturbed the elim- 
ination kinetics of F-ara-ATP, an action that was depen- 
dent on the duration of the ara-C infusion. In K562 cells, 
the elimination kinetics of F-ara-ATP were not changed by 
prior incubation with ara-C [14]. The experimental condi- 
tions, however, differed from the in vivo situation in that 
the dose of F-ara-A was 30-fold that of ara-C and the cells 
were washed free of ara-C prior to the addition of F-ara-A. 
As predicted from the preclinical data [14, 15], CLL 
cells accumulated less F-ara-ATP when the patients had 
received ara-C at 20 h prior to fludarabine administration 
(Fig. 3 A, B). In patients with acute leukemias, two higher 
ara-C dose levels (1 g/m2 over 2 h and 3 g/m2 over 6 h) 
were combined with the standard fludarabine dose 
(30 mg/m 2 over 30 rain). Because fludarabine as a single 
agent had shown no clinical efficacy in acute leukemias at 
this dose [33] and was used to modulate ara-C metabolism 
in our treatment protocols, the protocol design precluded 
the study of peak F-ara-ATP concentrations in cells that 
had not previously been exposed to ara-C. However, the 
median Cmax of accumulated F-ara-ATP in patients who 
received the higher ara-C dose was considerably lower 
(60%) than that in patients treated with the lower ara-C 
dose (Table 1). A likely explanation for this effect would 
be a feedback inhibition of dCyd kinase by ara-CTP [7, 14, 
28]. In cell-free extracts of K562 cells, the activity of dCyd 
kinase was previously inhibited by the addition of 100 gM 
ara-CTP [14]. Thus, it is possible that the ara-CTP concen- 
trations at the time of fludarabine infusion [range, 
8-63 gM (n = 7); Table 1] were sufficient to exert feed- 
back inhibition of dCyd kinase in the clinical setting [17]. 
198 
It seems rather unlikely that the peak concentration of 
F-ara-ATP was influenced by the second ara-C dose given 
at 4 h after the start of the fludarabine infusion, as the time 
to reach peak F-ara-ATP concentrations was the same 
(3 __+ 1 h) in patients treated in the presence versus the ab- 
sence of additional ara-C. 
The following mechanisms should be considered as ex- 
planations for the ara-C-induced perturbations in plasma 
F-ara-A and, consequently, the pharmacokinetics of F-ara- 
ATP in leukemia cells. First, consider renal excretion, 
which is the major route of F-ara-A elimination [23, 27]. 
Although deamination is responsible for ara-C clearance, 
the deamination product arabinosyluracil, a substrate for 
renal excretion, had reached plasma levels of between 50 
and 250 gM by the end of the ara-C infusions [17]. Had the 
renal excretion mechanism been saturated by arabino- 
syluracil, a plateau followed by a prolonged terminal half- 
life would have been expected rather than the observed 
increase in F-ara-A plasma levels followed by their rapid 
elimination (Fig. 1, Table 1). Furthermore, prolonged 
elevation of F-ara-A plasma levels should have translated 
into higher rather than lower intracellular concentrations of 
F-ara-ATP. Therefore, it is unlikely that a competition 
between the two drugs for renal excretion sites was respon- 
sible for the altered F-ara-A elimination kinetics. 
Second, the possibility of F-ara-A release from leuke- 
mia cells as a consequence of rapid cell kill caused by 
ara-C is unlikely because the increase in F-ara-A plasma 
concentrations was measurable at 30 min after the onset of 
the ara-C infusion. An increase in plasma levels of 2- 
chlorodeoxyadenosine was previously observed upon lysis 
of CLL cells, but it occurred several days after drug infu- 
sions [4]. In contrast, no significant decrease in the number 
of leukemia cells was observed at the time at which plasma 
F-ara-A levels increased. 
Competition of the two nucleosides for transport into 
cells represents a third possibility of explaining the in- 
crease in plasma F-ara-A during ara-C infusion. It is likely 
that both F-ara-A and ara-C are substrates for the same 
high-capacity facilitated diffusion mechanism [31, 34]. At 
the time of ara-C infusion, plasma levels of F-ara-A ranged 
between 0.3 and 0.7 gM (Fig. 1). In contrast, ara-C concen- 
trations ranged from 16 to 61 gM, levels that might be 
expected to result in effective competition with F-ara-A for 
entry into cells. 
Finally, because both ara-C and F-ara-A are phosphory- 
lated by dCyd kinase, a competition for this enzyme is 
likely. The greater affinity of dCyd kinase for ara-C 
(Kin = 15-41 gM [5, 9, 11, 26]; present study) as compared 
with F-ara-A (Krn = 290-1600 gM [2, 16]; present study) 
and the differences in plasma concentrations (ara-C levels 
were 20-50 times greater than those of F-ara-A) support 
this interpretation. Furthermore, ara-C was found to com- 
petitively inhibit F-ara-A phosphorylation in an in vitro 
experiment using purified dCyd kinase (Fig. 4). Ara-C 
concentrations in the range of the Ki value determined in 
this experiment (11.9 ~tM) w e r e  reached or exceeded in the 
plasma of patients treated with either 0.5 or 1 g/m 2 over 2 h 
(13 __ 4 gM and 23 + 8 gtM, respectively) or 3 g/m 2 over 6 h 
(27 __ 9 gM; Table 1). In addition, the activity of dCyd ki- 
nase may be inhibited by ara-CTP [7, 14, 28]. The ara-CTP 
concentrations present at the time of fludarabine infusion 
(Table 1) lay within the range reported to affect the activity 
of dCyd kinase. 
In conclusion, the inhibitory effect of ara-C on the accu- 
mulation of F-ara-ATP found in preclinical experiments 
using leukemia cells was confirmed in the clinical setting 
by the present study. On the basis of the considerations 
discussed above, in a protocol using F-ara-A as a biochem- 
ical modulator of ara-C, the ara-C should be given as a 
relatively short-term (e. g., 2 - 4  h) infusion following flud- 
arabine. This design would help to minimize metabolic 
interference with the subsequent fludarabine dose. 
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